GlassScriptPhysician profile
Jesse L Mace
NPI 1275975237
$9,164.04
in general payments reported to CMS, 2019-2025
44 companies · $1,474 in 2025
The $1,474 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,749 · 2022: $3,816 · 2023: $1,493 · 2024: $632 · 2025: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,598.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,555.23 | 2021-2025 | Breztri, Airsupra, Fasenra |
| Abbott Laboratories | $829.29 | 2021-2024 | Aveir |
| Glaxosmithkline, LLC. | $793.04 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Harmony Biosciences LLC | $637.32 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $622.29 | 2021-2025 | Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $397.73 | 2021-2022 | |
| Grifols USA, LLC | $391.12 | 2021-2025 | Prolastin-C Liquid |
| Amgen INC. | $306.46 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $295.44 | 2022-2025 | Mounjaro, Emgality, Jardiance |
| Regeneron Healthcare Solutions, INC. | $266.06 | 2021-2022 | |
| Novo Nordisk INC | $226.65 | 2025 | Ozempic, Wegovy |
| Abbvie INC. | $225.84 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $225.34 | 2021-2022 | |
| Medtronic, INC. | $224.55 | 2021 | |
| United Therapeutics Corporation | $192.66 | 2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Mace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.